Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic preservative-free latanoprost + timolol versus Xalacom in open-angle glaucoma or ocular hypertension
2017-004524-29Phase 3Completed
- Sponsor
- Pharmathen
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing Test preservative-free latanoprost + timolol with Xalacom active control (2 arms). Primary endpoint: Change in intraocular pressure at 8:00 am from baseline to week 12. Started Jan 2018; status: completed.
02
Drugs
latanoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2017-004524-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004524-29.